Anne Nunes - Oct 1, 2024 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
SVP, Chief Operations Officer
Signature
/s/ Anne Nunes
Stock symbol
ANIK
Transactions as of
Oct 1, 2024
Transactions value $
-$17,766
Form type
4
Date filed
10/4/2024, 04:06 PM
Previous filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise $0 +2.49K +21.25% $0.00 14.2K Oct 1, 2024 Direct F1, F2
transaction ANIK Common Stock Tax liability -$17.8K -732 -5.15% $24.27 13.5K Oct 1, 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Options Exercise $0 -2.49K -100% $0.00 0 Oct 1, 2024 Common Stock 2.49K $0.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the third and final vesting installment of RSUs granted on October 1, 2021.
F2 Includes 634 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 14, 2024.
F3 Reflects an aggregate of 732 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on October 1, 2024.
F4 Reflects the closing price of ANIK common stock on October 1, 2024, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
F5 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning October 1, 2022.